Recruiting PHASE2 INTERVENTIONAL 3-arm NCT03957902

Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer

Sponsor: G. d'Annunzio University

Updated 6 times since 2019 Last updated: Feb 25, 2025 Started: May 6, 2019 Primary completion: May 31, 2025 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03957902, this PHASE2 trial focuses on Colorectal Cancer and remains actively recruiting participants. Sponsored by G. d'Annunzio University, it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Mar 2025 — Present [monthly]

Recruiting PHASE2

Status: Unknown → Recruiting
Sep 2024 — Mar 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Jun 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

G. d'Annunzio University
Hospital Clínico Universitario Lozano Blesa
Instituto de Investigación Sanitaria Aragón
Instituto de Salud Carlos III

Data source: Instituto de Investigación Sanitaria Aragón

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zaragoza, Spain